EW vs BAX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EW Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Edwards Lifesciences Corp (EW) driven by superior Growth & Margin, Momentum & Technical while BAX counters with relative strength in Valuation, Options & Structure. Fundamentally, EW trades at 31.6x Forward P/E with 28.8% operating margin (+10.5% YoY revenue) versus BAX at 12.6x Forward P/E and 7.6% operating margin (+5.0% YoY). In options structure, EW sits in UNCLASSIFIED (34th %ile IV; Dealer Gamma Walls on Pro) against BAX sits in CONSOLIDATION (23rd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EW Revenue | BAX Revenue | EW Op. Margin | BAX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $3.72B | $11.1B | 20.1% | 14.3% | EW |
| FY2019 | $4.35B | $11.4B | 26.4% | 15.6% | EW |
| FY2020 | $4.39B | $11.7B | 20.5% | 13.8% | EW |
| FY2021 | $5.23B | $12.2B | 32.3% | 11.1% | EW |
| FY2022 | $4.46B | $10.1B | 33.6% | -28.3% | EW |
| FY2023 | $5.01B | $10.4B | 26.1% | 6.8% | EW |
| FY2024 | $5.44B | $10.6B | 25.3% | 0.1% | EW |
| FY2025 | $6.07B | $11.2B | 20.8% | -2.7% | EW |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EW | BAX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $60.8B | $13.3B | Larger Scale | EW |
| Trailing P/E Ratio Valuation | 61.5x | 12.4x | Lower Multiple | BAX |
| Forward P/E Ratio Valuation | 31.6x | 12.6x | Lower Multiple | BAX |
| Revenue Growth (YoY) Growth | +10.5% | +5.0% | Higher Growth | EW |
| Operating Margin (TTM) Profitability | 28.8% | 7.6% | Higher Margin | EW |
| Net Profit Margin Profitability | 15.3% | -6.2% | Higher Margin | EW |
| Return on Equity (ROE) Capital Efficiency | 9.3% | -9.0% | Higher ROE | EW |
| 52-Week Range Position Momentum | 96% ($75โ$108) | 69% ($16โ$30) | Stronger Trend | EW |
| Beta / 30D Volatility Risk Regime | 0.44ฮฒ ยท 24% Vol | 0.96ฮฒ ยท 48% Vol | Lower Realized Risk | EW |
| Unified Institutional Score Composite Signal | 31.5 / 100 (SELL) | 33.7 / 100 (SELL) | Higher Composite | BAX |